Significance of a Phase III Study on Docetaxel With Hormonal & Radiation Therapy in Prostate Cancer

July 15, 2015
Howard M. Sandler, MD, MS, FASTRO

Howard M. Sandler, MD, MS, FASTRO, Chair, Radiation Oncology, Ronald H. Bloom Family Chair, Cancer Therapeutics, Cedars Sinai, discusses the significance of a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Sandler states that prostate cancer is one of the four most common cancers, with the other three being breast, lung, and colon. The data from this study is the first to show an indication that agiment chemotherapy may have a role in localized non-metastatic prostate cancer.

Going forward, Sandler would like to allow the data to mature more than four years so that they can have more data to work with.

Howard M. Sandler, MD, MS, FASTRO, Chair, Radiation Oncology, Ronald H. Bloom Family Chair, Cancer Therapeutics, Cedars Sinai, discusses the significance of a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.